Chang et al, engineered a novel anti-B7-H4/IL15 fusion antibody, which enhances the immunogenicity of the TME by fostering the proliferation of CD8+ T cell and facilitating the elimination of B7H4-expressing tumor cells by activated immune cells, including ADCC dependent cellular cytotoxicity (76).These studies strongly suggest bispecific antibodies targeting B7-H4 is a promising therapeutic agent. The gene discussed is VTCN1; the disease is neoplasm.